+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinase-2 concentrations in squamous cell carcinoma of the head and neck and its clinical significance



Matrix metalloproteinase-2 concentrations in squamous cell carcinoma of the head and neck and its clinical significance



Nihon Jibiinkoka Gakkai Kaiho 99(2): 299-305



Tumor cells degrade extracellular matrix components (ECM) to invade surrounding tissues. Cancer cells are known to produce various ECM-degrading enzymes including matrix metalloproteinases (MMPs), serine proteinases and cathepsins. Type IV collagen is one of the major components of the basement membrane, and it composes the structural scaffold of these specialized sheets of the ECM. The enzymatic degradation of type IV collagen is initiated by MMPs, in particular MMP-2 (a 72 kDa type IV collagenase) and MMP-9 (a 92 kDa type IV collagenase) which play a key role in cancer invasion and metastasis. In this study, we investigated MMP-2 concentrations and the activity of type IV collagenase in cancer tissue homogenate in 21 cases with head and neck carcinomas and 6 cases with normal mucosa. MMP-2 concentrations did not differ between normal mucosa and tumor tissue without lymphnode metastases. Type IV collagenase activity in normal mucosa was below the detection limit. MMP-2 concentrations had no relation to tumor size, however MMP-2 concentrations in tumor tissue with lymphnode metastases were higher than that in cases without lymphnode metastasis (35.8 +/- 20.5, 20.0 +/- 9.7 ng/mg protein, respectively). However, there was no correlation between MMP-2 concentrations and type IV activity in tumor tissues. These results suggest that MMP-2 plays an important role in tumor invasion and metastasis, so MMP-2 could be a useful biological tumor marker for metastasis and prognosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 046631252

Download citation: RISBibTeXText

PMID: 8851335

DOI: 10.3950/jibiinkoka.99.299


Related references

Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Human Pathology 31(8): 895-904, 2000

Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: Studies of clinical samples and in vitro cell lines co-cultured with fibroblasts. Cancer Letters 150(1): 15-21, March 13, 2000

Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: studies of clinical samples and in vitro cell lines co-cultured with fibroblasts. Cancer Letters 150(1): 15-21, 2001

Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncology 41(3): 283-293, 2005

Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Laboratory 62(8): 1569-1574, 2017

Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Research 20(5a): 3045-3049, 2000

Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. International Journal of Cancer 116(3): 422-427, 2005

Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Letters 211(1): 19-24, 2004

Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clinical Cancer Research 10(9): 3110-3116, 2004

Matrix metalloproteinase (MMP) and immunosuppressive biomarker profiles of seven head and neck squamous cell carcinoma (HNSCC) cell lines. Translational Cancer Research 7(3): 533-542, 2018

Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncology 46(7): 514-518, 2011

Chemokine receptor 7 enhances cell chemotaxis and migration of metastatic squamous cell carcinoma of head and neck through activation of matrix metalloproteinase-9. Oncology Reports 32(2): 794-800, 2015

Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clinical Cancer Research 10(8): 2594-2599, 2004

Role of membrane type 1-matrix metalloproteinase and gelatinase A in head and neck squamous cell carcinoma invasion in vitro. Otolaryngology - Head & Neck Surgery 121(4): 337-343, 1999

Inostamycin accumulates G1 phase associated with suppression of cyclin D1 and inhibits matrix metalloproteinase 2 and 9 production in squamous cell carcinoma of the head and neck. Clinical & Experimental Metastasis 17(9): 767, 1999( ), 2000